Production (Stage)
Connect Biopharma Holdings Limited
CNTB
$0.95
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | -16.10% | -20.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 103.73% | 141.21% |
| Total Operating Expenses | -- | -- | -- | -36.94% | -38.36% |
| Operating Income | -- | -- | -- | 50.19% | 38.36% |
| Income Before Tax | -- | -- | -- | 60.02% | 47.76% |
| Income Tax Expenses | -- | -- | -- | -54.83% | -57.95% |
| Earnings from Continuing Operations | -- | -- | -- | 60.01% | 47.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 60.01% | 47.78% |
| EBIT | -- | -- | -- | 50.19% | 38.36% |
| EBITDA | -- | -- | -- | 50.52% | 38.58% |
| EPS Basic | -- | -- | -- | 60.05% | 47.82% |
| Normalized Basic EPS | -- | -- | -- | 58.31% | 45.35% |
| EPS Diluted | -- | -- | -- | 59.83% | 47.63% |
| Normalized Diluted EPS | -- | -- | -- | 58.28% | 45.35% |
| Average Basic Shares Outstanding | -- | -- | -- | 0.12% | 0.07% |
| Average Diluted Shares Outstanding | -- | -- | -- | 0.31% | 0.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |